Medulloblastoma in Adults: Cytogenetic Phenotypes Identify Prognostic Subgroups.


Journal

Journal of neuropathology and experimental neurology
ISSN: 1554-6578
Titre abrégé: J Neuropathol Exp Neurol
Pays: England
ID NLM: 2985192R

Informations de publication

Date de publication:
16 04 2021
Historique:
entrez: 19 4 2021
pubmed: 20 4 2021
medline: 30 12 2021
Statut: ppublish

Résumé

Adult medulloblastomas (MB) are rare. We investigated the genetic landscape and prognostic impact of genetic aberrations in a cohort of 117 adult medulloblastomas. Histological features and pathway activation were evaluated at the protein level; 14.5% showed wingless-type activation, 63.3% SHH activation, and 22.2% were classified as non-WNT/non-SHH-MB. Genome-wide copy number analysis was performed by molecular inversion probe array technology. MB-related genes were sequenced in WNT- and SHH-activated MBs. 79.7% of SHH-MBs showed desmoplastic/nodular histology; all other MBs had classic histology. WNT-MBs carried oncogenic CTNNB1 mutations in 88.2% and had monosomy 6 in 52.9%. In SHH-MBs, TERT promoter mutations occurred in 97%, mutations in PTCH1 in 38.2%, SMO in 15.5%, SUFU in 7.4%, and TP53-mutations in 4.1%. In all, 84.6% of non-WNT/non-SHH-MBs had an isochromosome 17q. A whole chromosomal aberration (WCA) signature was present in 45.1% of SHH-TP53-wild type (wt)-MBs and 65.4% of non-WNT/non-SHH-MBs. In 98 cases with survival data, WNT-MBs had a 5-year overall survival (OS) of 68.6%. SHH-MBs TP53wt type and non-WNT/non-SHH-MBs showed 5-year OS of 80.4% and 70.8%, respectively. TP53-mutant SHH-MBs represented a prognostically unfavorable entity; all patients died within 5 years. Patients with a WCA signature showed significantly increased OS (p = 0.011 for SHH-TP53wt-MBs and p = 0.048 for non-WNT/non-SHH-MBs).

Identifiants

pubmed: 33870422
pii: 6231147
doi: 10.1093/jnen/nlab020
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

419-430

Informations de copyright

© 2021 American Association of Neuropathologists, Inc. All rights reserved.

Auteurs

Tobias Goschzik (T)

From the Department of Neuropathology, University of Bonn Medical Center, Bonn, Germany.

Anja Zur Muehlen (A)

From the Department of Neuropathology, University of Bonn Medical Center, Bonn, Germany.

Evelyn Doerner (E)

From the Department of Neuropathology, University of Bonn Medical Center, Bonn, Germany.

Andreas Waha (A)

From the Department of Neuropathology, University of Bonn Medical Center, Bonn, Germany.

Carsten Friedrich (C)

Division of Pediatric Oncology and Hematology, University Children's Hospital Rostock, Rostock, Germany.

Peter Hau (P)

Department of Neurology and Wilhelm Sander NeuroOncology Unit, Regensburg University Hospital, Regensburg, Germany.

Torsten Pietsch (T)

From the Department of Neuropathology, University of Bonn Medical Center, Bonn, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH